On November 7, 2025, Serina Therapeutics held its Annual Meeting where two directors, Steve Ledger and Karen J. Wilson, were elected; auditors were ratified, and a proposal for convertible notes and warrants was approved. The voting results showed a strong majority in favor of these proposals, indicating confidence in the company's direction.